Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) [0.03%]
Juying Wei,Qingqing Cai,Liling Zhang et al.
Juying Wei et al.
Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patien...
Clinical Trial
Blood cancer journal. 2026 Mar 17;16(1):36. DOI:10.1038/s41408-026-01452-8 2026
Fang Cheng,Yu Wang,Yunfan Yang et al.
Fang Cheng et al.
Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies [0.03%]
血液系统恶性肿瘤CAR-T细胞治疗后的皮肤不良反应
Elvira Umyarova,John Sharp,Charles Pei et al.
Elvira Umyarova et al.
Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification [0.03%]
基于IPSS-R、IPSS-M和国际共识分类的骨髓增生异常综合征遗传及转录组学异常的预后意义
Wan-Hsuan Lee,Hsin-An Hou,Chien-Chin Lin et al.
Wan-Hsuan Lee et al.
Cytogenetic abnormalities and recurrent gene mutations are central to the biology and prognosis of myelodysplastic syndromes/neoplasms (MDS); however, the significance of patients without detectable genomic lesions remains unclear. In this ...
Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma [0.03%]
BIRC5和MCL-1的抑制作为潜在的治疗策略来克服套细胞淋巴瘤的药物耐药性
Jeremiah Pfitzer,Sayak Chakravarti,Suman Mazumder et al.
Jeremiah Pfitzer et al.
Mohamad Mohty,Florent Malard,Thierry Facon et al.
Mohamad Mohty et al.
Multiple myeloma (MM), long viewed as incurable, is entering a transformative era marked by deeper remissions, prolonged survival, and the realistic prospect of cure. The greatest opportunity lies at diagnosis, before genomic heterogeneity ...
Anti-PD-1 antibody combined with P-GEMOX chemotherapy versus P-GEMOX chemotherapy with or without autologous stem-cell transplantation for previously untreated advanced natural killer/T cell lymphoma: a retrospective cohort study [0.03%]
针对既往未接受治疗的晚期自然杀伤/T细胞淋巴瘤患者，抗PD-1抗体联合P-GEMOX化疗对比P-GEMOX化疗加或不加自体干细胞移植：一项回顾性队列研究
Qihua Zou,Yi Cao,Liang Wang et al.
Qihua Zou et al.
We evaluated the effectiveness of adding anti-PD-1 antibody to P-GEMOX regimen in previously untreated advanced-stage natural killer/T-cell lymphoma (NKTCL) compared to P-GEMOX alone or with autologous stem cell transplantation (ASCT). 418 ...
Long-term outcomes of autologous stem cell transplantation for AL amyloidosis: a 15-year experience from a Chinese referral center and a comparison of different eras [0.03%]
中国自体干细胞移植治疗AL淀粉样变性长期疗效及不同年代间比较：单中心15年经验
Mengnan Liu,Jinzhou Guo,Wencui Chen et al.
Mengnan Liu et al.
Stephen M Ansell,Grzegorz S Nowakowski
Stephen M Ansell
Diffuse large B-cell lymphoma (DLBCL) is an aggressive B-cell malignancy and is the most common subtype of lymphoma. Treatment is administered with curative intent and approximately two thirds of patients are expected to have durable long-t...
Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia [0.03%]
染色体正常急性髓系白血病患者基因组结构变异对其预后的评估有贡献作用
Niccolò Bartalucci,Francesco Mannelli,Danilo Tarantino et al.
Niccolò Bartalucci et al.
Cytogenetic and genomic profiling of acute myeloid leukemia (AML) guides personalized treatment according to ELN2022 recommendations. However, marked outcome variability persists among cytogenetically normal (CN-) patients, representing an ...